Can a novel computerized cognitive screening test provide additional information for early detection of Alzheimer's disease?

Virtual reality testing of everyday activities is a novel type of computerized assessment that measures cognitive, executive, and motor performance as a screening tool for early dementia. This study used a virtual reality day‐out task (VR‐DOT) environment to evaluate its predictive value in patients with mild cognitive impairment (MCI).

[1]  R Irimajiri,et al.  Cortical event-related potentials in preclinical familial Alzheimer disease , 2009, Neurology.

[2]  L A Beckett,et al.  Age-specific incidence of Alzheimer's disease in a community population. , 1995, JAMA.

[3]  Vasilios K Kimiskidis,et al.  Event-related potentials for the diagnosis of mild cognitive impairment and Alzheimer's disease. , 2012, Expert opinion on medical diagnostics.

[4]  Frederick A. Schmitt,et al.  Improving dementia care: The role of screening and detection of cognitive impairment , 2013, Alzheimer's & Dementia.

[5]  J. Hobart,et al.  Putting the Alzheimer's cognitive test to the test II: Rasch Measurement Theory , 2013, Alzheimer's & Dementia.

[6]  J. Morris,et al.  The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals , 2008, Cerebral cortex.

[7]  Ronald C. Petersen,et al.  Assessment of cognition in mild cognitive impairment: A comparative study , 2011, Alzheimer's & Dementia.

[8]  Georg Juckel,et al.  Diagnostic Usefulness of Cognitive Auditory Event-Related P300 Subcomponents in Patients With Alzheimers Disease? , 2008, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

[9]  C. Jack,et al.  Mild cognitive impairment: ten years later. , 2009, Archives of neurology.

[10]  Nickolai Titov,et al.  The effects of distraction on prospective remembering following traumatic brain injury assessed in a simulated naturalistic environment , 2006, Journal of the International Neuropsychological Society.

[11]  Gérard Rondouin,et al.  Can Event-Related Potential Predict the Progression of Mild Cognitive Impairment? , 2011, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

[12]  R. Brookmeyer,et al.  National estimates of the prevalence of Alzheimer’s disease in the United States , 2011, Alzheimer's & Dementia.

[13]  Ioannis Tarnanas,et al.  Ecological Validity of Virtual Reality Daily Living Activities Screening for Early Dementia: Longitudinal Study , 2013, JMIR serious games.

[14]  M. Carrillo,et al.  Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer's disease and its precursors: A new approach , 2013, Alzheimer's & Dementia.

[15]  N. Titov,et al.  Use of Virtual Reality Tasks to Assess Prospective Memory: Applicability and Evidence , 2009, Brain Impairment.

[16]  Miranka Wirth,et al.  Alzheimer's Disease Neurodegenerative Biomarkers Are Associated with Decreased Cognitive Function but Not β-Amyloid in Cognitively Normal Older Individuals , 2013, The Journal of Neuroscience.

[17]  C. Brayne,et al.  The Incidence of Dementia in England and Wales: Findings from the Five Identical Sites of the MRC CFA Study , 2005, PLoS medicine.

[18]  Evelyne Klinger,et al.  Use of the Virtual Action Planning Supermarket for the Diagnosis of Mild Cognitive Impairment , 2009, Dementia and Geriatric Cognitive Disorders.

[19]  J. Lirng,et al.  Prediction of Alzheimer's disease in mild cognitive impairment: A prospective study in Taiwan , 2006, Neurobiology of Aging.

[20]  E. Cavedo,et al.  Cognitive decline and cerebrospinal fluid biomarkers: a close relationship , 2013 .

[21]  Nick C Fox,et al.  The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease , 2011 .

[22]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[23]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[24]  G. Schellenberg,et al.  Dementia and Alzheimer disease incidence: a prospective cohort study. , 2002, Archives of neurology.

[25]  B Isaacs,et al.  The set test: a rapid test of mental function in old people. , 1972, Age and ageing.

[26]  Adriana M. Seelye,et al.  Status of computerized cognitive testing in aging: A systematic review , 2008, Alzheimer's & Dementia.

[27]  R. C. Oldfield.  The assessment and analysis of handedness: the Edinburgh inventory. , 1971, Neuropsychologia.

[28]  H. Buschke,et al.  Screening for dementia by memory testing , 1988, Neurology.

[29]  Magda Tsolaki,et al.  Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study , 2009, The Lancet Neurology.

[30]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[31]  Keith A. Johnson,et al.  Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer’s disease , 2011, Alzheimer's & Dementia.

[32]  T. Tombaugh.  Trail Making Test A and B: normative data stratified by age and education. , 2004, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

[33]  Henrik Zetterberg,et al.  Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. , 2012, Archives of general psychiatry.

[34]  J. Trojanowski,et al.  Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. , 2010, Archives of neurology.

[35]  E. Tangalos,et al.  Neuropathologic features of amnestic mild cognitive impairment. , 2006, Archives of neurology.

[36]  Reisa A. Sperling,et al.  Executive function and instrumental activities of daily living in mild cognitive impairment and Alzheimer's disease , 2011, Alzheimer's & Dementia.

[37]  Ronald C. Petersen,et al.  Mild cognitive impairment clinical trials , 2003, Nature Reviews Drug Discovery.

[38]  E. Tangalos,et al.  CME Practice parameter: , 2022 .

[39]  C. Jack,et al.  MRI and CSF biomarkers in normal, MCI, and AD subjects , 2009, Neurology.

[40]  Dong Young Lee,et al.  Predictive validity and diagnostic stability of mild cognitive impairment subtypes , 2012, Alzheimer's & Dementia.

[41]  Z. Khachaturian,et al.  Biomarker development: A population-level perspective , 2012, Alzheimer's & Dementia.

[42]  J. Polich,et al.  P300 as a clinical assay: rationale, evaluation, and findings. , 2000, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[43]  M. Tsolaki,et al.  Combination of P300 and CSF β-amyloid(1-42) assays may provide a potential tool in the early diagnosis of Alzheimer's disease. , 2010, Current Alzheimer research.

[44]  Bradford C. Dickerson,et al.  Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau , 2013, Front. Aging Neurosci..

[45]  L. Fried,et al.  Executive decline and dysfunction precedes declines in memory: the Women's Health and Aging Study II. , 2009, The journals of gerontology. Series A, Biological sciences and medical sciences.

[46]  Phoebe E. Bailey,et al.  Dismantling the “age–prospective memory paradox”: The classic laboratory paradigm simulated in a naturalistic setting , 2010, Quarterly journal of experimental psychology.

[47]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[48]  M. Mintun,et al.  Amyloid deposition, hypometabolism, and longitudinal cognitive decline , 2012, Annals of neurology.

[49]  David A Loewenstein,et al.  Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions , 2010, Alzheimer's Research & Therapy.